Related Experiment Video
Updated: Jun 15, 2025
Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
Myasthenia gravis
Mamatha Pasnoor1, Gil I Wolfe2, Richard J Barohn3
1Department of Neurology, University of Kansas Medical Center, Kansas City, KS, United States.
Abstract:
Myasthenia gravis (MG) is a rare neuromuscular junction disorder that is characterized by fatigable weakness of muscles. People with MG experience various clinical manifestations based on the muscles involved. MG can be autoimmune, paraneoplastic, congenital, medication-related, or transient in the neonatal period due to the passive placental transfer of antibodies from mothers with MG. Acetylcholine receptor antibodies are seen in the majority of patients with MG. However, other antibodies have been discovered in the last 20 years, including muscle-specific tyrosine kinase (MuSK) and lipoprotein-related peptide 4 (LRP4), and are now available through commercial testing. More recently, a handful of other antibodies have been associated with MG; however, they are not presently available for routine testing. A disease classification system has been developed by the Myasthenia Gravis Foundation of America (MGFA) and is commonly used worldwide. A number of objective and subjective outcome measures have been developed and validated over the years and have been proven useful for both clinical and research purposes, serving as primary and secondary outcome measures in most clinical trials. A growing number of therapies are available for both acute and chronic management of MG, with several new mechanistic approaches under investigation. An international consensus guidance for the management of MG was first published in 2016 and updated in 2020.
Insights
Myasthenia gravis (MG) is a rare neuromuscular disorder causing muscle weakness. Research highlights diagnostic antibodies, classification systems, outcome measures, and evolving therapies for MG management.
Area of Science:
- Neurology
- Immunology
- Genetics
Background:
- Myasthenia gravis (MG) is a rare neuromuscular junction disorder.
- Characterized by fatigable muscle weakness, MG presents with diverse clinical manifestations.
- MG can stem from autoimmune, paraneoplastic, congenital, medication-related causes, or transient neonatal transfer.
Purpose of the Study:
- To provide an overview of Myasthenia Gravis.
- To discuss diagnostic advancements, classification, and outcome measures.
- To review current and emerging therapeutic strategies for MG.
Main Methods:
- Literature review of MG pathophysiology, diagnosis, and treatment.
- Analysis of diagnostic antibody testing, including acetylcholine receptor, MuSK, and LRP4 antibodies.
- Examination of the Myasthenia Gravis Foundation of America (MGFA) classification system and outcome measures.
Main Results:
- Acetylcholine receptor antibodies are prevalent in MG; MuSK and LRP4 antibodies are also significant diagnostic markers.
- Validated objective and subjective outcome measures are crucial for clinical trials and research.
- International consensus guidance for MG management was updated in 2020, reflecting advancements in care.
Conclusions:
- MG diagnosis and management have advanced with the discovery of new antibodies and standardized approaches.
- Therapeutic options for MG are expanding, with novel mechanistic therapies under investigation.
- Continued research and updated clinical guidelines are essential for optimizing patient outcomes in Myasthenia Gravis.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
01:15Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:28Disorders of the Skeletal Muscle
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
01:26Chemical Synapses
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
01:10Muscle Contraction
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...